3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 1
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
CNS
2
Conditions
Carcinoma, Non-Small-Cell Lung
4
Lung Neoplasms
2
Brain Neoplasms
2
Respiratory Tract Diseases
1
Neoplasms
1
Meningeal Carcinomatosis
1
Interventions
Radiosurgery
27
Radiotherapy
17
Magnetic Resonance Spectroscopy
14
Erlotinib Hydrochloride
14
Bevacizumab
13
Pemetrexed
10
Carboplatin
10
pembrolizumab
9
Gefitinib
9
osimertinib
8
icotinib
7
Temozolomide
7
Nivolumab
6
Specimen Handling
5
Paclitaxel
5
Spermine Synthase
4
Mental Status and Dementia Tests
4
Ipilimumab
4
Drug Therapy
4
Cisplatin
4
atezolizumab
3
alectinib
3
aflutinib
3
Radiation
3
Immunotherapy
3
Fluorodeoxyglucose F18
3
regorafenib
2
paclitaxel-Angiopep-2 conjugate
2
motexafin gadolinium
2
epothilone B
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Brain Neoplasms
×
AZD3759
×
Thoracic
×
Clear all
NCT03653546
2025-09-10
BM
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3
Completed
492 enrolled
NCT02228369
2021-01-05
BLOOM
AstraZeneca
Phase 1
Completed
108 enrolled